Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound for treating erectile dysfunction of men

A technology of erectile dysfunction and compound, which is applied in the field of medicine, can solve the problems of low incidence of back pain and audio-visual impairment, etc., and achieve the effect of long drug effect time, increased blood flow and remarkable effect

Active Publication Date: 2019-08-02
北京精华耀邦医药科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, the high selectivity of avanafil results in fewer side effects than other similar products, and a lower incidence of back pain and hearing impairment
However, avanafil can still cause adverse reactions such as back pain, dizziness, headache, palpitations, vision or hearing loss, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound for treating erectile dysfunction of men
  • Compound for treating erectile dysfunction of men
  • Compound for treating erectile dysfunction of men

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Randomly select 20 volunteers who suffer from male erectile dysfunction disease, and are divided into two groups on average, with 10 people in each group. The first group of volunteers takes the medicine 100 mg for treating male erectile dysfunction of the present invention, and the second group of volunteers After taking 100 mg of avanafil tablets, the onset time and duration of drug effects of the two drugs were counted, and the physical symptoms of the two groups of volunteers were observed.

[0017] The first group of statistical results shows that the onset time of the medicine of the present invention is 40-120 minutes, and the maintenance time of the drug effect morning erection is about 5-10 days. Adverse reactions;

[0018] The second set of statistics shows that the onset time of avanafil tablets is 20-40 minutes, and the duration of drug effect is 4-6 hours. Adverse reactions such as headache, dizziness, and palpitations may occur, and in severe cases, sudde...

Embodiment 2

[0021] Randomly select 20 volunteers suffering from male erectile dysfunction disease, and divide them into two groups on average, with 10 people in each group. The volunteers in the first group take 100 mg of avanafil tablets first, and take 100 mg of the medicine of the present invention after the efficacy of the drug fails. The second group of volunteers first took 100 mg of the drug of the present invention, and then took 100 mg of avanafil tablets after the efficacy of the drug failed, and then observed the symptoms of the two groups of volunteers in terms of physical fitness.

[0022] Observation results found that after the first group of volunteers took avanafil tablets, adverse reactions such as backache and back pain occurred, and after the efficacy of the drug failed, the above adverse reactions disappeared gradually; the second group of volunteers took the medicine of the present invention Afterwards, no adverse reactions occurred, and after taking avanafil tablets ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound for treating an erectile dysfunction of men. The compound has a chemical formula of (S)-4-(3-chloro-4-methoxybenzylamino)-2-(2-(propoxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmetyl-1)pyrimidin-5-formamido-hydrochloride and is obtained through hydroxyl alkylation of avanafil. The compound can inhibit metabolism of cyclic guanosine monophosphate in a body after being taken, so that the relaxant effect of smooth muscle is reinforced, blood flow of a penis is increased, erection is further assisted, the compound has long efficacy and has a remarkable effect whenused for treating an erectile dysfunction of men, particularly, the early morning erection effect is remarkable after the compound is used for a period of time, the men can unconsciously and spontaneously erect in the early morning from 4 o'clock to 7 o'clock, and the compound has no side effects; the compound can be used for treating climacteric syndrome of women, depression and backpain causedby fatigue, can relieve side effects such as palpitation, flushing, energielos and the like caused by nafil drugs and is favorable for removing dampness, moistening the intestines, relaxing the bowelsand promoting diuresis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a compound for treating male erectile dysfunction. Background technique [0002] Avanafil (avanafil) is a drug developed by American Vivus Company authorized by Tanabe Mitsubishi Pharmaceutical Co., Ltd. for the treatment of male erectile dysfunction (ED). It was approved by the US FDA on April 27, 2012. The trade name is Stendra, which is an oral, fast-acting, highly selective phosphodiesterase-5 (PDE-5) inhibitor. The chemical formula of avanafil is 4-[(3-chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidine Chloromethyl)-5-pyrimidinecarboxamide, English name: 4-[(3-Chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl) -5-pyrimidinecarboxamid, the molecular formula is C 23 h 26 ClN 7 o 3 , the molecular weight is 483.9506, and the density is 1.373g / cm 3 , the structural formula is [0003] [0004] Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D403/14A61P15/10A61P15/12A61P25/24A61P27/02A61P27/16A61P9/06A61P1/08
CPCA61P1/08A61P9/06A61P15/10A61P15/12A61P25/24A61P27/02A61P27/16C07D403/14
Inventor 卫永刚陈宁王正濂
Owner 北京精华耀邦医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com